Results 231 to 240 of about 203,270 (263)
Some of the next articles are maybe not open access.
Immunosuppressive agents and asthma
Clinical Reviews in Allergy, 1994One of the goals of asthma therapy is to maintain control of symptoms without producing unwanted effects from asthma medications. Corticosteroids are the mainstay for intractable chronic asthma, but their long-term use in high doses is limited by the risk of significant adverse effects.
openaire +3 more sources
Glucocorticosteroids as immunosuppressive agents
Seminars in Veterinary Medicine and Surgery: Small Animal, 1997When administered at pharmacological dosages, glucocorticosteroid hormones alter leukocyte kinetics, phagocytic cell function, cell-mediated immunity, and, to a lesser extent, humoral immunity. These properties are used to advantage in the treatment of immunologically mediated disease.
openaire +2 more sources
Dermatologic Therapy With Immunosuppressive Agents
Postgraduate Medicine, 1975The use of powerful immunosuppressive agents such as methotrexate, cyclophosphamide, and azathioprine in the treatment of serious skin diseases is a relatively recent development whose efficacy is borne out in many studies. Using an immunosuppressant often makes possible an appreciable reduction in dosage of steroid necessary to control disease and, in
Robert I. Rudolph, James J. Leyden
openaire +3 more sources
Neurologic Complications of Immunosuppressive Agents
Neurologic Clinics, 1988The immunosuppressive agents that are an integral part of organ transplantation serve to protect grafts from rejection as well as to prevent or treat GVHD. They include CsA, corticosteroids, OKT3 monoclonal antibody, HDARA-C, azathioprine, and ATG. Of these, all but azathioprine and ATG have direct neurologic complications that are due to the drugs ...
Russell W. Walker, Joel A. Brochstein
openaire +3 more sources
The Pharmacokinetics and Pharmacodynamics of Immunosuppressive Agents
Critical Care Nursing Clinics of North America, 1992Designing immunosuppressive regimens for the pediatric transplant patient is challenging because one must balance the need to provide adequate immunosuppression without interfering with normal growth processes or causing long-term adverse consequences.
Kathleen D. Lake +2 more
openaire +3 more sources
Tacrolimus: a new immunosuppressive agent
American Journal of Health-System Pharmacy, 1995The mechanism of action, pharmacokinetics, drug interactions, clinical efficacy, and adverse effects of tacrolimus, a newly approved immunosuppressant drug for use in the prophylaxis of organ rejection after transplantation, are reviewed. Tacrolimus prevents rejection of the transplanted organ by inhibiting the expression of interleukin-2 in T cells ...
Gilbert J. Burckart +2 more
openaire +3 more sources
2001
In the 1990’s, many new small and large molecules have been discovered and developed for use as immunosuppressants in transplantation. This chapter focuses on those small molecules that have shown to have immunosuppressive activity in patients1,2 (Fig.1).
Tuija Ikonen +2 more
openaire +2 more sources
In the 1990’s, many new small and large molecules have been discovered and developed for use as immunosuppressants in transplantation. This chapter focuses on those small molecules that have shown to have immunosuppressive activity in patients1,2 (Fig.1).
Tuija Ikonen +2 more
openaire +2 more sources
Bacterial endotoxins as immunosuppressive agents
Experientia, 1971Der Adjuvanseffekt von bakteriellem Endotoxin gegenuber Schaferythrocyten war nicht nachweisbar, wenn Mause vor der primaren antigenen Stimulierung 9 Tage lang eine tagliche Injektion von 20 µg Endotoxin erhielten. Andererseits wurde unter diesen Bedingungen eine Primarreaktion gefunden, wie sie nach alleiniger Injektion des Erythrocytenantigens zur ...
H. Fresenius, M. Angerer, H. Finger
openaire +3 more sources
Experimental Immunosuppressive Agents
2001Today, many new small and large molecular weight molecules are being developed for use as immunosuppressive agents. As the understanding of mechanisms of immune function improves, immunosuppressive drug discovery and development is able to more specifically target activation pathways that predominate in immune rather than nonimmune cells, thus ...
Jochen Klupp, Randall E. Morris
openaire +2 more sources
Immunosuppressive Agents on the Horizon
Journal of Pharmacy Practice, 2003The evolution of immunosuppression in organ transplantation has resulted in decreasing rates of rejection and improved allograft survival. The current successes, however, comes at the price of intense drug monitoring, frequent adverse affects, and long-term toxicity.
openaire +2 more sources